Murine polyomavirus-VP1 virus-like particles immunize against some polyomavirus-induced tumours.
The ability of murine polyomavirus (MPyV)-VP1 virus-like particles (MPyV-VLPs) to immunize against MPyV tumour outgrowth was investigated. Non-immunized and mice immunized three times were challenged with MPyV or non-MPyV tumours and followed for tumour outgrowth. MPyV-VLP immunization abrogated outgrowth of some, but not all, tested MPyV tumours and delayed the outgrowth of a non-MPyV tumour to some extent. However, when mice were irradiated prior to tumour challenge to avoid an unspecific immune response, protection was MPyV-specific. In conclusion, VLP immunization for prevention of viral infection could also contribute to immune-protection against some tumours induced by the corresponding virus.
Franzén
Andrea Vlastos
AV
Department of Oncology-Pathology, Karolinska Institute, Cancer Center Karolinska R8:01, Karolinska Hospital, SE-171 76 Stockholm, Sweden.
Tegerstedt
Karin
K
Holländerova
Dana
D
Forstová
Jitka
J
Ramqvist
Torbjörn
T
Dalianis
Tina
T
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D045744:Cell Line, Tumor; D005982:Glutathione Transferase / Q000235:genetics; D007114:Immunization; D051379:Mice; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D011120:Polyomavirus / Q000276:immunology*; D027601:Polyomavirus Infections / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D014779:Virus Replication
D000951:Antigens, Neoplasm; D036022:Capsid Proteins; D011993:Recombinant Fusion Proteins; C062481:VP1 protein, polyomavirus; D005982:Glutathione Transferase